AVR catalysts
Catalysts and events linked to AVR, newest first.
AVR stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Anteris Secures German BfArM Regulatory Clearance for DurAVR PARADIGM Trial 2026-10-20 · Up | regulatory approval derisking clinical pipeline progression | Anteris Technologies received BfArM regulatory clearance to initiate PARADIGM trial for DurAVR in Germany | Not recorded |
| Anteris wins German BfArM clearance for DurAVR PARADIGM heart valve trial 2026-10-20 · Up | clinical pathway milestone progress toward European commercialization | BfArM clearance allows Anteris to initiate PARADIGM patient recruitment in Germany. | Not recorded |
Do these developments change your position?
Review AVR alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-10-20Anteris Secures German BfArM Regulatory Clearance for DurAVR PARADIGM TrialAVR
- 2026-10-20Anteris wins German BfArM clearance for DurAVR PARADIGM heart valve trialAVR
- 2026-10-20Anteris Secures German BfArM Regulatory Clearance for DurAVR PARADIGM TrialAVR
- 2026-10-20Anteris wins German BfArM clearance for DurAVR PARADIGM heart valve trialAVR EW
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.